Funding profile · Oncology diagnostics

Delee

One Form D and three Regulation Crowdfunding offerings, totalling about $2.75 million between 2019 and 2022, against reported revenue of zero in every disclosed year. The filings stop in July 2023.

$2.75MTotal documented in SEC filings, 2019 to 2022
$1.18MForm D offering, sold in full to 4 investors
$1.58MClosed across three crowdfunding offerings
$0.00Revenue reported for every fiscal year through 2022

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Winter 2017 Y Combinator batch Not disclosed Y Combinator; later StartX YC directory
Filed Dec 2019 SAFE, first sale Jan 11, 2017 $1,175,000 sold of $1,175,000 4 accredited investors Form D
Closed Apr 24, 2020 Crowd SAFE, Republic, $10M cap $1,070,000 Retail crowd Form C-U
Closed Apr 6, 2022 Series Seed V Preferred, StartEngine, $1.66 per share $288,398.77 and 195,066 securities Retail crowd Form C-U
Closed Dec 17, 2022 Crowd SAFE, Republic, $22M valuation $219,259.46 in commitments Retail crowd Form C-U
To Dec 2022 Company summary of the same capital “over $2.6M USD”, including “over $1.4M USD on equity crowdfunding from more than 5250 investors” Named: Y Combinator, StartX, Emles venture partners Company-stated

What the filings show

Delee Corp · Form D · filed Dec 9, 2019

First sale
Jan 11, 2017
Offered
$1,175,000, options to acquire and other securities
Sold
$1,175,000 · $0 remaining
Investors
4 · average $293,750
Exemption
Rule 506(b)
Related persons
Liza Velarde, Alejandro Abarca Blanco and Juan Yee de Leon (executive officers and directors); Joost Leeflang (director)
Filing
SEC EDGAR, CIK 0001790674

Delee Corp · Form C and Form C-U · 2019 to 2022

Portals
OpenDeal Portal LLC (Republic) in 2019 and 2022; StartEngine Capital LLC in 2021
Securities
Crowd SAFE in both Republic rounds; Series Seed V Preferred Stock at $1.66 on StartEngine
Targets
$1,070,000 maximum in 2020; $4,999,998.02 maximum in 2022; $4,000,000 maximum in 2022
Closed
$1,070,000 · $288,398.77 · $219,259.46
Portal fee
6 percent of the amount raised plus securities equal to 2 percent of those sold
Filing
SEC EDGAR, CIK 0001790674

Delee Corp · Form C-AR · filed Jul 24, 2023 for fiscal 2022

Revenue
$0.00 in 2022 and $0.00 in 2021
Net income
Loss of $37,205 in 2022 after a loss of $444,284 in 2021
Cash
$87,049.32 at year end 2022 · $75,402 a year earlier
Total assets
$1,445,405 · up from $253,337
Short term debt
$126,086 · up from $76,086
Employees
3
Signed by
Liza Paola Velarde Calvillo (CEO), Alejandro Abarca Blanco (CTO), Juan Felipe Yee de Leon (CMO)

Reading the filings

  1. The private round was four large cheques.$1,175,000 divided among 4 investors is $293,750 each. That is institutional or family office size, not an angel list, and it matches a board seat going to a former Philips Healthcare executive.
  2. The Form D was filed about 35 months late.The notice reports a first sale on January 11, 2017 and was filed on December 9, 2019. Rule 503 calls for filing within 15 days of the first sale. The filing date lines up with the first Republic campaign, which suggests the notice was prepared because a portal required a clean record rather than at the time money moved.
  3. Each crowd round was smaller than the last.$1,070,000 in 2020, then $288,398.77 in 2022, then $219,259.46 in 2022. The valuation moved the other way, from a $10 million cap to $22 million. Raising less at more than twice the price is the signature of a round priced on a story rather than on demand.
  4. The reported and the filed totals differ.Kingscrowd records $347,498 for the StartEngine round and $204,059 for the December 2022 Republic round. The issuer’s own Form C-U filings state $288,398.77 and $219,259.46. Commitments that are cancelled or fail to clear explain a gap in one direction, not both.
  5. The 2022 balance sheet does not behave like an operating company.Total assets rose from $253,337 to $1,445,405 while cash stayed near $87,000 and the annual loss fell to $37,205. A near sixfold jump in assets with almost no cash and almost no spending points to something non-cash carrying the balance sheet, most plausibly capitalised development or intangibles, not to a business buying equipment and hiring.
  6. The crowd paid about $300 each.$1,577,658 across the three crowdfunding closes, against the company’s own count of more than 5,250 investors, averages roughly $300 a head. Those holders have no information rights and no board seat, and the annual report that would have told them anything stopped after fiscal 2022.

Commercial signals

Signal Detail Source type
Regulatory No FDA 510(k), premarket approval or device establishment registration. No COFEPRIS or CE record found. Sold as research use only, where none is required. Public record
Revenue $0.00 reported for every fiscal year disclosed to the SEC through 2022. Public record
Pre-orders $1.2M, then $1.4M in 2019, then over $2.5M in 2021 and 2022, from hospital research centres. Not named beyond Stanford and a Monterrey university hospital, and never converted to revenue. Differs from filings
Evidence Two Scientific Reports papers, 2019 and 2020. The larger prostate cohort promised in 2020 has not been published. No registered trial. Public record
Headcount 17 full time staff claimed in 2021; 3 reported for fiscal 2022; the Y Combinator directory still shows 18. Differs from filings
Web presence delee.co, the issuer website named in the SEC filings, now returns an unrelated online gambling page. Public record

What to watch

  • A Form C-AR covering fiscal 2023 or later, or a Form C-TR terminating the reporting obligation. Neither has been filed.
  • Any assignment or sale of the CytoCatch patents, which would show where the asset went.
  • A new Form D under any successor entity carrying the same officers.
  • Publication of the larger prostate cohort, wherever the samples ended up.

The Delee story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • X-ZELL: Also in Diagnostics. A Singapore and Bangkok company that set out to find early cancer in a 10mL blood draw, published one 146 patient prostate study, then turned the staining machine built
  • Notable Labs: Also in Diagnostics. A blood cancer company that screened drugs against a patient’s own cells to predict who would respond, in-licensed a shelved Boehringer Ingelheim compound, reached
  • Clear Gene: Also in Diagnostics. An RNA test built to tell a surgeon whether the whole tumor came out
  • Isabl: Also in Diagnostics. A Memorial Sloan Kettering spin out that reads the whole tumor genome and transcriptome instead of a gene panel

Sources

  1. Public recordForm D, Delee Corp, CIK 0001790674SEC EDGAR · Dec 9, 2019
  2. Public recordForm C-U progress updates, three offeringsSEC EDGAR · 2020 to 2022
  3. Public recordForm C offering statement, Delee CorpSEC EDGAR · Jun 3, 2022
  4. Public recordForm C-AR annual report for fiscal year 2022SEC EDGAR · Jul 24, 2023
  5. Public recordEDGAR filing history, CIK 0001790674SEC EDGAR · accessed Sep 22, 2026
  6. Public recordopenFDA and ClinicalTrials.gov queries for Delee and CytoCatchFDA, ClinicalTrials.gov · Sep 22, 2026
  7. IndependentDelee deal pages with round, valuation and financial tablesKingscrowd · 2019 to 2022
  8. InterviewDelee Co-Founder Liza Velarde on Improving and Personalizing Cancer TreatmentKingscrowd · Nov 5, 2021
  9. CompanyDelee offering pages, traction and funding claimsRepublic · 2019 and 2022
  10. CompanyDelee directory entry, batch, team size, statusY Combinator · accessed Sep 22, 2026

Compiled from SEC, FDA and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D and Form C filings report offerings under Regulation Crowdfunding; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Delee. This page is not an offer to sell or a recommendation to buy any security.